PD-1 blockade improve STING + anti-GITR therapy. Mice bearing 2 A20 tumors were treated as described in Figure 1C. Mice were treated with IT STINGa and IP anti-PD-1, IT STING and IP anti-GITR, IP anti-GITR and IP anti-PD-1, or, the triple combination, IT STINGa, IP anti-GITR and IP anti-PD-1. Treatment efficacy was assessed measuring tumor growth at the treated site (A), tumor growth at the distant nontreated site (B), and overall survival (C). (A-B) One experiment with 10 mice per group. Experiment was repeated twice. Error bars are SEM. Statistical significance of tumor growth was calculated using 2-way ANOVA. (C) Data pulled from 2 experiment with 10 mice per group. Survival significance was calculated using Mantel-Cox. *P < .05; **P < .01; ***P < .001.